CN102488688A - Ophthalmic preparation by taking fibrauretinumrecisapierre as main drug - Google Patents
Ophthalmic preparation by taking fibrauretinumrecisapierre as main drug Download PDFInfo
- Publication number
- CN102488688A CN102488688A CN2011103982450A CN201110398245A CN102488688A CN 102488688 A CN102488688 A CN 102488688A CN 2011103982450 A CN2011103982450 A CN 2011103982450A CN 201110398245 A CN201110398245 A CN 201110398245A CN 102488688 A CN102488688 A CN 102488688A
- Authority
- CN
- China
- Prior art keywords
- fibrauretin
- eye
- ophthalmic preparation
- eye drop
- fibrauretinumrecisapierre
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an ophthalmic preparation by taking fibrauretinumrecisapierre as a main drug. The ophthalmic preparation prepared by the fibrauretinumrecisapierre comprises eye drops, oculentum, ophthalmic liposome, inclusion compound eye drops and the like through the following steps of: taking the fibrauretinumrecisapierre as an active ingredient and adding minor ingredients for the ophthalmic preparation; and contains the raw components in weight ratio: 0.01-2 percent of fibrauretinumrecisapierre, and the balance of the minor ingredients for the ophthalmic preparation. The experiment results prove that the ophthalmic preparation cannot cause irritant inflammatory reaction, and has better inhibiting effect on conjunctivitis and better stability.
Description
Technical field
The present invention relates to medical technical field, specifically is to be the ophthalmic preparation of principal agent with the fibrauretin.
Background technology
Conjunctivitis (conjunctivitis) is the commonly encountered diseases of ophthalmology, the general designation of the inflammatory reaction that to be conjunctival tissue take place in the effect of extraneous and body oneself factor.Because most of conjunctiva directly contacts with extraneous; Therefore receive easily infectious in the surrounding (as antibacterial, virus, and chlamydia etc.) and the stimulation of non-infectious factor (wound, chemical substance and physical factor etc.); And the blood vessel of conjunctiva and lymphoid tissue are abundant, and self and extraneous antigen make its sensitization easily.
Mostly the medicine eye drop that is used at present treat is Western medicine prepn, clinical response weak curative effect and side reaction is arranged.The treatment of conjunctivitis is if the acute viral conjunctivitis can be put with steroid (can ground pine) collyrium, to alleviate the state of an illness.Bacterial conjunctivitis, available non-irritating irrigation are like 2% boric acid water or normal saline flushing conjunctival sac, and a local effective antibiotic collyrium frequently is coated with the antibiotic eye ointment before sleeping.For pure Chinese medicinal preparation---fibrauretin eye drop is adopted in this this test.
Fibrauretin has functions such as heat-clearing and toxic substances removing, antiinflammatory.With the Caulis Fibraureae is the fibrauretin of raw material production; Composition is main with palmatine (palmatine), has formed preparations such as fibrauretin sheet, capsule, injection, has pharmacological actions such as broad-spectrum antiseptic, antiviral; To the urinary system infection determined curative effect, particularly remarkable to the gynecological infection curative effect especially.
Fibrauretin has another name called palmatine hydrochloride, is the alkaloids substance in a kind of Chinese medicine source, from traditional Chinese medicine Caulis Fibraureae
Fibraurea tinctoriaCentral extraction separation obtains.Fibrauretin belongs to the proto-berberine in the Bian Ji Tetrahydroisoquinoli-beautiful jade Alkaloid, has biological action comparatively widely.Present research shows that fibrauretin has significant anti-several diseases pathogenic microorganism and protozoacide effect; Multiple Gram-positive and negative bacterium are had significant inhibitory effect, multiple fungus such as Candida albicans, achorion gypseum, Fonsecaea pedrosor etc. are also had stronger inhibitory action.In addition, discover that fibrauretin also has immunoregulation effect, strengthen body defence function thereby can strengthen leukocytic phagocytosis.Oral formulations, the injection of fibrauretin are widely used in gynecological inflammation, dysentery, enteritis, respiratory tract and urinary tract infection, surgical infection etc. clinically at present.But fibrauretin only has oral formulations or injection, no fibrauretin eye drop product in existing product at present.
Summary of the invention
The purpose of this invention is to provide a kind of fibrauretin ophthalmic preparation with better effects treatment conjunctivitis.
Fibrauretin ophthalmic preparation of the present invention comprises that eye drop, eye ointment, eye are with liposome, clathrate eye drop etc.
Technical scheme of the present invention is: the weight proportion of the raw material components of the fibrauretin ophthalmic preparation of treatment conjunctivitis is: fibrauretin 0.01～2%, all the other are the pharmaceutic adjuvant of ophthalmic preparation.
The weight proportion of the raw material components of the fibrauretin ophthalmic preparation of treatment conjunctivitis is: fibrauretin 0.7%, all the other are adjuvant.
The various components of fibrauretin ophthalmic preparation of the present invention are following:
A, eye drop preparation:
Fibrauretin 0.01～2%
PH regulator agent 0.1～15%
Isoosmotic adjusting agent 0.2～10%
Antiseptic 0.02～1%
Antioxidant 0.05～5%
Water surplus.
B, eye are used Liposomal formulation:
Fibrauretin 0.01～2%
PH regulator agent 0.1～15%
Isoosmotic adjusting agent 0.2～10%
Liposome material 0.5～30%
Antiseptic 0.02～1%
Antioxidant 0.05～5%
Water surplus.
C, eye ointment preparation:
Fibrauretin 0.01～2%
Antiseptic 0.02～1%
Antioxidant 0.05～5%
Eye is used the substrate surplus.
D, eye are used inclusion compound eye drops:
Fibrauretin 0.01～2%
Clathrate 0.2～30%
PH regulator agent 0.1～15%
Isoosmotic adjusting agent 0.2～10%
Antiseptic 0.02～1%
Antioxidant 0.05～5%
Water surplus.
Described pH regulator agent is one or more of sodium hydroxide, organic amine and/or mineral acid and salt, organic acid and salt thereof, sodium carbonate, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate, boric acid, Borax.
Described thickening agent is one or more in Polyethylene Glycol, hyaluronic acid sodium, carbomer, poloxamer, methylcellulose, Carboxymethyl cellulose sodium, hypromellose, polyvinyl alcohol, polyvinylpyrrolidone and the sodium alginate.
Described isoosmotic adjusting agent is one or more in sodium oxide, glucose, sodium acetate, sodium carbonate, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate, boric acid, Borax, propylene glycol, the glycerin mannitol.
Described antioxidant is one or more in sodium sulfite, sodium sulfite and sodium pyrosulfite, sodium thiosulfate, disodiumedetate (EDTA), arabo-ascorbic acid and sodium salt thereof, the thiourea.
Described eye pasting substrate is one or more in aliphatic alcohol, Yellow Vaselin, white vaseline, lanoline and the white oil.
Described eye uses the liposome membrane material as lecithin, PHOSPHATIDYL ETHANOLAMINE (PE), fabaceous lecithin, cholesterol, cephalin, cholesterol acetyl fat, cupreol, natrii tauroglycocholas, Yolk lecithin, synthesize in two palmityls-DL-α phosphatidylcholine (DPPC), synthetic phospholipid acyl silk amino acid (PS), phosphatidylinositols (PI), sphingomyelin (SPH), sphingo (DCP), two myristoyl lecithin (DMPC), the stearmide (SA) one or more.
The clathrate material of described clathrate eye drop is cyclodextrin (CD), beta-schardinger dextrin-(β-CD) and second-HP-(one or more of HP-β-CD).
Described antiseptic is one or more in thimerosal, phenylmercuric acetate, chlorobutanol, benzalkonium chloride, benzyl alcohol, phenethanol, sorbic acid and the Buddhist nun's platinum esters.
Fibrauretin ophthalmic preparation of the present invention has good inhibitory effect through the inflammatory reaction of experimental verification nonirritant to conjunctivitis, and has stability preferably.
The specific embodiment
Embodiment 1:
Preparation fibrauretin eye drop:
Get water for injection 750g, add sodium oxide 2.5g, boric acid 12g, Borax 1.5g, the happy golden ethyl ester 0.3g of Ni Bo, sodium sulfite 1g, EDTA1g; Stirring makes dissolving, adds fibrauretin 0.1g again, stirs to make its dissolving; Regulating pH value is 7.0, adds water to 1000ml, crosses the 0.22um filtering with microporous membrane; Aseptic subpackaged in eye drop bottle, packing promptly gets.
Embodiment 2:
Preparation fibrauretin eye drop:
Get water for injection 750g, add sodium oxide 4g, sodium dihydrogen phosphate 1.6g, sodium hydrogen phosphate 7.5g, phenethanol 1g, sodium sulfite 1g, EDTA1g; Stirring makes dissolving, adds fibrauretin 7g again, stirs to make its dissolving; Add water to 1000ml; Cross the 0.22um filtering with microporous membrane, aseptic subpackaged in eye drop bottle, packing promptly gets.
Embodiment 3:
Preparation fibrauretin eye drop:
Get water for injection 750g, add sodium oxide 4g, sodium dihydrogen phosphate 1.6g, sodium hydrogen phosphate 7.5g, phenethanol 1g, sodium sulfite 1g, EDTA1g; Stirring makes dissolving, adds fibrauretin 20g again, stirs to make its dissolving; Add water to 1000ml; Cross the 0.22um filtering with microporous membrane, aseptic subpackaged in eye drop bottle, packing promptly gets.
Embodiment 4:
Preparation fibrauretin eye ointment
Yellow Vaselin 800g, anhydrous lanolin 100g are heated to 150 ℃ of fusings, are incubated 1 hour postcooling to 60 ℃, be eye pasting substrate, subsequent use; Other gets fibrauretin 20g, grinds well with the 50g liquid paraffin, and the equivalent incremental method is added in the above-mentioned eye pasting substrate, adds the sterilization Yellow Vaselin to total amount 1000g, and stirs it is fully decomposed evenly, sieve through 180 mesh sieves, and cooling, packing is packed and is promptly got.
Embodiment 5:
Preparation fibrauretin eye ointment
White vaseline 800g, anhydrous lanolin 100g, liquid paraffin 50g are heated to 150 ℃ of fusings, are incubated 1 hour postcooling to 60 ℃, be eye pasting substrate, subsequent use; Other gets fibrauretin 7g, adds water for injection 20g, and using sodium bicarbonate to regulate pH value is 7.0, stirs it is uniformly dispersed; Add thimerosal 10g, stir and make dissolving, above-mentioned solution is through the 0.22um filtering with microporous membrane; Add an amount of eye pasting substrate and be ground into fine and smooth pasty state, the equivalent incremental method is added in the above-mentioned eye pasting substrate to total amount 1000g again, and stirs it is fully decomposed evenly; Sieve through 180 mesh sieves; Cooling, packing, packing promptly gets.
Embodiment 6:
Preparation fibrauretin eye ointment
White vaseline 500g, anhydrous lanolin 100g, liquid paraffin 100g are heated to 150 ℃ of fusings, are incubated 1 hour postcooling to 60 ℃, be eye pasting substrate, subsequent use; Other gets fibrauretin 0.1g, adds water for injection 75g, and using sodium bicarbonate to regulate pH value is 7.2, stirs it is uniformly dispersed; Add ethyl hydroxybenzoate 3g, sodium sulfite 1g, stir and make dissolving, above-mentioned solution is through the 0.22um filtering with microporous membrane; Add an amount of eye pasting substrate and be ground into fine and smooth pasty state, the equivalent incremental method is added in the above-mentioned eye pasting substrate to total amount 1000g again, and stirs it is fully decomposed evenly; Sieve through 180 mesh sieves; Cooling, packing, packing promptly gets.
Embodiment 7:
Preparation fibrauretin liposome:
Get water for injection 250g, add fibrauretin 1.5g, Nepal tortoise beetle ester 2.5g, sodium dihydrogen phosphate 1.65g, sodium hydrogen phosphate 33.7g, sodium sulfite 2.5g, stir and make its dissolving; Get phosphatidase 12 0g, cholesterol 5g, be dissolved among the ether 50g, stir and make dissolving; With above-mentioned two liquid mixings, add water to total amount 1000g, mixing, sonic oscillation 30 minutes changes in the thin film evaporation appearance, and ethanol evaporation is to most, and above-mentioned solution is through the 0.22um filtering with microporous membrane.Aseptic subpackaged, packing promptly gets.
Embodiment 8:
Preparation fibrauretin liposome:
Get water for injection 250g, add fibrauretin 20g, nipagin ester 2.5g, sodium dihydrogen phosphate 1.65g, sodium hydrogen phosphate 33.7g, sodium sulfite 2.5g, stir and make its dissolving; Get phosphatidase 12 0g, cholesterol 5g, be dissolved among the ether 50g, stir and make dissolving; With above-mentioned two liquid mixings, add water to total amount 1000g, mixing, sonic oscillation 30 minutes changes in the thin film evaporation appearance, and ethanol evaporation is to most, and above-mentioned solution is through the 0.22um filtering with microporous membrane.Aseptic subpackaged, packing promptly gets.
Embodiment 9:
Preparation fibrauretin liposome:
Get water for injection 250g, add fibrauretin 0.1g, Nepal tortoise beetle ester 2.5g, sodium dihydrogen phosphate 1.65g, sodium hydrogen phosphate 33.7g, sodium sulfite 2.5g, stir and make its dissolving; Get phosphatidase 12 0g, cholesterol 5g, be dissolved among the ether 50g, stir and make dissolving; With above-mentioned two liquid mixings, add water to total amount 1000g, mixing, sonic oscillation 30 minutes changes in the thin film evaporation appearance, and ethanol evaporation is to most, and above-mentioned solution is through the 0.22um filtering with microporous membrane.Aseptic subpackaged, packing promptly gets.
Embodiment 10:
Preparation fibrauretin inclusion compound eye drops
Get beta-schardinger dextrin-10g, add water for injection 750g, heating makes dissolving, adds fibrauretin 1g, stirs and makes its dissolving; Put ultrasonator ultrasonic 10 minutes, and added sodium chloride 4g, boric acid 8g, Borax 6g, nipagin ester 2.5g, sodium sulfite 1g more successively, stir and make dissolving.Using sodium carbonate to regulate pH is 6.5, adds water to total amount 1000g mixing, and above-mentioned solution is through the 0.22um filtering with microporous membrane.Aseptic subpackaged, packing promptly gets.
Embodiment 11:
Preparation fibrauretin inclusion compound eye drops
Get beta-schardinger dextrin-10g, add water for injection 750g, heating makes dissolving, adds fibrauretin 20g, stirs and makes its dissolving; Put ultrasonator ultrasonic 10 minutes, and added sodium chloride 4g, boric acid 8g, Borax 6g, nipagin ester 2.5g, sodium sulfite 1g more successively, stir and make dissolving.Using sodium carbonate to regulate pH is 6.5, adds water to total amount 1000g mixing, and above-mentioned solution is through the 0.22um filtering with microporous membrane.Aseptic subpackaged, packing promptly gets.
Embodiment 12:
Preparation fibrauretin inclusion compound eye drops
Get second-HP-20g, add water for injection 750g, heating makes dissolving, adds fibrauretin 0.1g, stirs and makes its dissolving; Put ultrasonator ultrasonic 10 minutes, and added sodium chloride 4g, boric acid 8g, Borax 6g, nipagin ester 2.5g, sodium sulfite 1g more successively, stir and make dissolving.Using sodium carbonate to regulate pH is 6.5, adds water to total amount 1000g mixing, above-mentioned solution.
Employing extracorporeal bacteria inhibitor test, irritation test, antiinflammatory test make an experiment to its curative effect with stability test and verify
1, the extracorporeal bacteria inhibitor test of fibrauretin eye drop (embodiment 2)
The preparation of bacteria suspension: be seeded to hemophilus influenza, staphylococcus aureus, streptococcus pneumoniae, escherichia coli, bacillus pyocyaneus, 6 kinds of lyophilizing bacterial strains of staphylococcus epidermidis in the serum broth respectively earlier; Cultivate 18 h for 37 ℃; Picking one encircles in microbionation to the 5 mL serum broth respectively from each enrichment liquid, 37 ℃ of 18 h, centrifugal (2000 r/min; 10 min), supernatant discarded; With physiological saline solution washing, recentrifuge; Each pipe deposition is diluted with physiological saline solution.Adopt turbidimetry to make 5 kinds of bacteria suspension concentration be 1 * 105 CFU/mL, subsequent use.
Diluted sample adopts test tube serial dilution method, is that 0.7% fibrauretin eye drop sample is diluted to 6 different dilution factors with serum broth with mass percentage concentration, and promptly 1/2,1/4,1/8,1/16,1/32 and 1/64.
Microbionation will be than in the bacterial suspension inoculation after turbid to the pastille meat soup, and inoculum concentration is 50 μ L/ pipes.Set up the positive, feminine gender and blank group, wherein positive control simultaneously: not dosing adds bacterium; Negative control: add the ampicillin of 80 μ g/mL, add bacterium; Blank: dosing does not add bacterium.
After cultivating 24 h in 37 ℃ of incubators of bacteria cultivation results, the situation of observing each bacterial growth.Confirm as minimum inhibitory concentration (MIC) with the least concentration of finer contained drug.Each picking one ring meat soup from finer is respectively on the flat board of streak inoculation to drug not.Cultivate 24 h for 37 ℃, observation has or not bacterium colony to form to confirm the minimum bactericidal concentration (MBC) of medicine.
The antibacterial action of table 1 fibrauretin eye drop
Can be known that by above bacteriostatic test mass percentage concentration is that the antibiotic minimum produce effects dosage of 0.7% fibrauretin eye drop sample is 1/8 dilution factor, this moment, sample concentration was 0.0875%.
2, the irritation test of fibrauretin eye drop (embodiment 3)
Get 6 of 18-22g mices, be divided into 2 groups at random.One group is blank group (distilled water), and one group is that mass percentage concentration is 2% fibrauretin eye drop drug group, and every 2h drips 1 time; Each 2-3 drips; And observe the animal activity situation, and put to death mice and get the nasopharynx part mucosa with the air tap inserting method behind the 24h, embathe with 10% formaldehyde immediately and send pathological biopsy.
The irritation test result: observe the mice behavior, mucosa, matched group and drug group inorganization morphological change, the result shows the inflammatory reaction of fibrauretin eye drop nonirritant.
4, the antiinflammatory of fibrauretin eye drop (embodiment 1) test
Through the animal inflammatory model, observe the inhibitory action of fibrauretin eye drop to inflammation.
(1) the fibrauretin eye drop is to the influence of rat paw edema due to the agar
Adopt the concentrated solution of fibrauretin eye drop, it is divided into 3 dose groups, every group contains the crude drug amount and is respectively 2mg/kg, 0.2mg/kg, 0.02mg/kg; Select 50 of healthy Wister rats for use.Body weight 130～190g, male and female are not limit, and divide physiology saline control group, fibrauretin eye drop 2mg/kg group, fibrauretin eye drop 0.2mg/kg group, fibrauretin eye drop 0.02mg/kg group at random.Smear the following position of rat paw and joint repeatedly with medicine before the Yu Zhiyan.Every day 5 times, 3d continuously.30min causes inflammation at rat paw subcutaneous injection 1% agar solution 0.05mL after the last administration, measures the change in volume that causes below the rat paw joint, scorching front and back.Each surveys 1 right hind ankle joint girth respectively at 1,3,5,24 h subsequently, and the record result is calculated as follows the swelling degree:
Girth * 100% before swelling degree (%)=(cause scorching back girth-cause scorching before girth)/cause is scorching
Table 3 fibrauretin eye drop is to the influence (
± s) of rat paw edema due to the agar
Fibrauretin eye drop therapeutic effect is remarkable, compares with matched group, and < 0.01, difference has statistical significance to P.
(2) the bullate influence of fibrauretin eye drop xylol induced mice ear
Adopt the concentrated solution of fibrauretin eye drop, it is divided into 3 dose groups.Select 50 of body weight 18 ~ 22g Kunming mouses for use, male and female are not limit.Be divided into 5 groups at random, i.e. normal saline matched group, furan fiber crops eye drop group, fibrauretin eye drop 2mg/kg group, fibrauretin eye drop 0.2mg/kg group, fibrauretin eye drop 0.02mg/kg group.Smear the mice left and right sides ear every day 5 times, continuously 3d.30min after the last administration drips xylene in mouse right ear, puts to death animal behind the 15min, with the 6mm card punch along the left and right sides auricle same area punch, the both sides auricle is weighed respectively, with two weight differences as the swelling level index.The difference of comparative drug group and matched group.Fibrauretin eye drop xylol induced mice ear is the bullate result of influence weigh respectively to mice both sides auricle; With two weight differences as the swelling level index; And the difference through comparative drug group and matched group, obtain the antiinflammatory action that inhibitory rate of intumesce is judged the fibrauretin eye drop.Suppression ratio=(model group swelling degree average-medication group swelling degree average)/model group swelling degree average * 100%.
The bullate influence of table 4 fibrauretin eye drop xylol induced mice ear
Fibrauretin eye drop therapeutic effect is remarkable, compares with matched group, and < 0.01, difference has statistical significance to P.
Extracorporeal bacteria inhibitor test, irritation test, antiinflammatory test experimental result through the fibrauretin eye drop can infer that the produce effects dosage of fibrauretin eye drop is 0.1%～2%.
5, the stability test of fibrauretin eye drop (embodiment 2)
(1) accelerated test
Sample is placed on 40 ℃ ± 2 ℃ of temperature, in the incubator of relative humidity 75% ± 5%, by 1,2,3, check June.
The result: the color of sample, clarity and pH value, content does not all change.
The stable case of table 5 sample in accelerated test three months
These article microbial limit test of drugs meets the microbial limit standard of nasal administration preparation in the version pharmacopeia in 2010, and product indicia thing content all in acceptability limit, shows that product is stable.
(2) investigation that keeps sample for a long time
The embedding of these article is sealed in 10 mL bottles, put 25 ℃ ± 2 ℃ of temperature, the following reserved sample observing of doing of relative humidity 60% ± 10% during respectively at 0,3,6,9,12 month, is observed mensuration to its color, clarity, pH value, deposition etc.
Labelled amount is respectively as a result: 100%, 100%, 98%, 97%, 95%.Its outward appearance and pH and content do not have significant change.
The stable case of table 6 sample in 12 months
These article medicine sanitary inspection meets the microbial limit standard of nasal administration preparation in the version pharmacopeia in 2010, and product indicia thing content all in acceptability limit, shows that product is stable.
Claims (7)
1. one kind is the ophthalmic preparation of principal agent with the fibrauretin, it is characterized in that the weight proportion of raw material components is: fibrauretin 0.01%～2%, all the other are adjuvant.
2. according to claim 1 is the ophthalmic preparation of principal agent with the fibrauretin, it is characterized in that the weight proportion of raw material components is: fibrauretin 0.7%, all the other are adjuvant.
3. according to claim 1 is the ophthalmic preparation of principal agent with the fibrauretin, it is characterized in that described ophthalmic preparation is that eye drop, eye ointment, eye are with liposome, clathrate eye drop.
4. fibrauretin eye drop is characterized in that being made up of following percentage by weight raw material:
Fibrauretin 0.01～2%
PH regulator agent 0.1～15%
Isoosmotic adjusting agent 0.2～10%
Antiseptic 0.02～1%
Antioxidant 0.05～5%
Water surplus.
5. fibrauretin liposome is characterized in that being made up of following percentage by weight raw material:
Fibrauretin 0.01～2%
PH regulator agent 0.1～15%
Isoosmotic adjusting agent 0.2～10%
Liposome material 0.5～30%
Antiseptic 0.02～1%
Antioxidant 0.05～5%
Water surplus.
6. oleaginous base fibrauretin eye ointment is characterized in that being made up of following percentage by weight raw material:
Fibrauretin 0.01～2%
Antiseptic 0.02～1%
Antioxidant 0.05～5%
Eye is used the substrate surplus.
7. a fibrauretin eye is used inclusion compound eye drops, it is characterized in that being made up of following percentage by weight raw material:
Fibrauretin 0.01～2%
Clathrate 0.2～30%
PH regulator agent 0.1～15%
Isoosmotic adjusting agent 0.2～10%
Antiseptic 0.02～1%
Antioxidant 0.05～5%
Water surplus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103982450A CN102488688A (en) | 2011-12-05 | 2011-12-05 | Ophthalmic preparation by taking fibrauretinumrecisapierre as main drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103982450A CN102488688A (en) | 2011-12-05 | 2011-12-05 | Ophthalmic preparation by taking fibrauretinumrecisapierre as main drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102488688A true CN102488688A (en) | 2012-06-13 |
Family
ID=46180595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103982450A Pending CN102488688A (en) | 2011-12-05 | 2011-12-05 | Ophthalmic preparation by taking fibrauretinumrecisapierre as main drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102488688A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127464A (en) * | 2014-07-15 | 2014-11-05 | 贵州大学 | Ophthalmic Blumea balsamifera oil preparation and preparation method thereof |
| CN104490765A (en) * | 2014-12-24 | 2015-04-08 | 昆明振华制药厂有限公司 | Palmatine ophthalmic gel and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634408A (en) * | 2004-10-25 | 2005-07-06 | 张帆 | Preparation method and application of Chinese medicinal preparation for ophthalmology |
| CN101058575A (en) * | 2006-04-21 | 2007-10-24 | 杭州豪迈医药科技有限公司 | Method of extracting and refining palmatin hydrochloride and application thereof |
-
2011
- 2011-12-05 CN CN2011103982450A patent/CN102488688A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634408A (en) * | 2004-10-25 | 2005-07-06 | 张帆 | Preparation method and application of Chinese medicinal preparation for ophthalmology |
| CN101058575A (en) * | 2006-04-21 | 2007-10-24 | 杭州豪迈医药科技有限公司 | Method of extracting and refining palmatin hydrochloride and application thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127464A (en) * | 2014-07-15 | 2014-11-05 | 贵州大学 | Ophthalmic Blumea balsamifera oil preparation and preparation method thereof |
| CN104127464B (en) * | 2014-07-15 | 2017-06-13 | 贵州大学 | A kind of blumea oil eye-drops preparations and preparation method thereof |
| CN104490765A (en) * | 2014-12-24 | 2015-04-08 | 昆明振华制药厂有限公司 | Palmatine ophthalmic gel and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366621C (en) | Plumepoppy total alkaloid salt and its prepn and application | |
| CN104940936B (en) | Treat the long-acting slow-release preparation and the preparation method and application thereof of fungal keratitis | |
| CN104127464A (en) | Ophthalmic Blumea balsamifera oil preparation and preparation method thereof | |
| CN103130865B (en) | Matrine, oxymatrine enoxolone double salt and preparation method thereof, purposes | |
| CN104145966B (en) | Chelerythrine application in preparing antimycotic biofilm medicine | |
| CN104069124B (en) | Compositions and preparation for gynecological infection | |
| CN102488688A (en) | Ophthalmic preparation by taking fibrauretinumrecisapierre as main drug | |
| CN108404111B (en) | A bacteriostatic and antiviral preparation containing semen Phaseoli vulgaris phytohemagglutinin as main ingredient | |
| JP3019996B2 (en) | Ringworm treatment | |
| CN101732244B (en) | Nose drops taking fibrauretine as main medicine and preparation method | |
| CN105232449A (en) | Moxifloxacin hydrochloride sodium hyaluronate controlled-release nanogel and preparation method thereof | |
| CN102918051A (en) | N6-(methylferrocene) quinazoline-2, 4, 6-triamine (H2) and derivatives thereof, and prodrugs for use as antibacterial, antiparasitic, antiprotozoal and antileishmanial agents | |
| CN110448527A (en) | A kind of colchicin oral administration solution and its composition | |
| CN101584715B (en) | Spray for preventing and treating skin damnification and resisting infection | |
| CN104667267A (en) | Lysozyme compound agent for skin external use and preparation method of lysozyme compound agent | |
| CN112107676B (en) | Lipopeptide and application thereof in antibiosis | |
| CN115919830A (en) | Application of butylparaben in enhancing antibacterial activity of polymyxin drugs | |
| CN102614294A (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| CN108066278B (en) | Gynecological gel containing chitosan oligosaccharide and preparation method thereof | |
| CN104288152A (en) | Compound berberine sulfate injection for veterinary use and preparation method thereof | |
| CN108420821A (en) | A kind of antimycotic topical composition of compound | |
| CN104274391A (en) | Rifaximin-containing pharmaceutical preparation | |
| CN108186705A (en) | A kind of anti-inflammatory gelling agent and preparation method thereof | |
| CN102648904B (en) | Application of curcumin-zinc compound in preparing health-care nursing product | |
| CN107970257A (en) | A kind of ear pharmaceutical composition, preparation method and applications and ear pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120613 |
|
| RJ01 | Rejection of invention patent application after publication |